Atea Pharmaceuticals (AVIR) Competitors $3.66 +0.13 (+3.68%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.61 -0.05 (-1.37%) As of 08/22/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. RCUS, LENZ, ZYME, SYRE, UPB, STOK, VERV, PRAX, VALN, and CRMDShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Arcus Biosciences (RCUS), LENZ Therapeutics (LENZ), Zymeworks (ZYME), Spyre Therapeutics (SYRE), Upstream Bio (UPB), Stoke Therapeutics (STOK), Verve Therapeutics (VERV), Praxis Precision Medicines (PRAX), Valneva (VALN), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors Arcus Biosciences LENZ Therapeutics Zymeworks Spyre Therapeutics Upstream Bio Stoke Therapeutics Verve Therapeutics Praxis Precision Medicines Valneva CorMedix Arcus Biosciences (NYSE:RCUS) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Does the media prefer RCUS or AVIR? In the previous week, Arcus Biosciences had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 2 mentions for Arcus Biosciences and 0 mentions for Atea Pharmaceuticals. Arcus Biosciences' average media sentiment score of 1.02 beat Atea Pharmaceuticals' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Overall Sentiment Arcus Biosciences Positive Atea Pharmaceuticals Neutral Do insiders & institutionals have more ownership in RCUS or AVIR? 92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, RCUS or AVIR? Atea Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$258M4.34-$283M-$3.17-3.32Atea PharmaceuticalsN/AN/A-$168.38M-$1.61-2.27 Is RCUS or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -109.56%. Atea Pharmaceuticals' return on equity of -32.55% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-109.56% -55.96% -25.73% Atea Pharmaceuticals N/A -32.55%-30.47% Which has more volatility and risk, RCUS or AVIR? Arcus Biosciences has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Do analysts prefer RCUS or AVIR? Arcus Biosciences presently has a consensus target price of $21.14, suggesting a potential upside of 101.19%. Atea Pharmaceuticals has a consensus target price of $6.00, suggesting a potential upside of 63.93%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryArcus Biosciences beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$280.13M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-2.2720.8831.1026.05Price / SalesN/A342.28432.51103.82Price / CashN/A43.1937.7358.48Price / Book0.808.129.536.61Net Income-$168.38M-$54.72M$3.26B$265.56M7 Day Performance4.57%2.63%2.10%1.97%1 Month Performance4.87%2.78%2.81%-0.36%1 Year Performance-6.15%11.01%30.56%19.03% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals1.7908 of 5 stars$3.66+3.7%$6.00+63.9%-3.2%$280.13MN/A-2.2770High Trading VolumeRCUSArcus Biosciences2.4173 of 5 stars$10.45+0.6%$21.14+102.3%-40.6%$1.11B$258M-3.30500Positive NewsLENZLENZ Therapeutics1.2811 of 5 stars$38.77+2.4%$49.60+27.9%+80.0%$1.08BN/A-20.41110Gap UpZYMEZymeworks0.279 of 5 stars$14.05-2.2%N/AN/A$1.08B$76.30M-14.48460SYRESpyre Therapeutics2.905 of 5 stars$16.94-0.1%$53.40+215.2%-29.8%$1.02B$890K-4.9873UPBUpstream Bio2.1487 of 5 stars$18.02-4.8%$56.50+213.5%N/A$1.02B$2.37M0.0038STOKStoke Therapeutics4.5662 of 5 stars$18.51+1.6%$25.57+38.1%+42.3%$997.86M$36.56M21.78100VERVVerve Therapeutics3.004 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110PRAXPraxis Precision Medicines1.7277 of 5 stars$46.63-1.0%$85.88+84.2%-2.0%$990.84M$8.55M-3.79110VALNValneva2.4266 of 5 stars$12.14+5.3%$15.50+27.7%+52.2%$981.14M$183.52M-12.39700Trending NewsAnalyst ForecastAnalyst RevisionGap UpCRMDCorMedix2.6959 of 5 stars$13.10+1.3%$16.71+27.6%+168.4%$965.21M$43.47M17.4730Positive News Related Companies and Tools Related Companies Arcus Biosciences Alternatives LENZ Therapeutics Alternatives Zymeworks Alternatives Spyre Therapeutics Alternatives Upstream Bio Alternatives Stoke Therapeutics Alternatives Verve Therapeutics Alternatives Praxis Precision Medicines Alternatives Valneva Alternatives CorMedix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access